interleukin-2 gene-modified tumor infiltrating lymphocytes

Interleukin-2 (IL-2) gene-modified tumor infiltrating lymphocytes (TILs) are an autologous adoptive cell therapy developed primarily by the National Cancer Institute (NCI). This therapy involves harvesting TILs from a patient's tumor, transducing them with a retroviral vector containing the IL-2 gene, and expanding them in vitro. The genetic modification is intended to allow the lymphocytes to secrete IL-2 locally, which may enhance their survival, proliferation, and anti-tumor activity within the tumor microenvironment while potentially reducing the need for high-dose systemic IL-2, which is associated with significant toxicity. This approach is typically used in a non-myeloablative setting following lymphodepleting chemotherapy (such as cyclophosphamide and fludarabine) for the treatment of metastatic melanoma.

Other names

IL-2 retroviral vector-transduced tumor-infiltrating lymphocytesIL2 retroviral vector-transduced tumor-infiltrating lymphocytesIL 2 retroviral vector-transduced tumor-infiltrating lymphocytesinterleukin-2 gene-transduced tumor-infiltrating lymphocytesinterleukin2 gene-transduced tumor-infiltrating lymphocytesinterleukin 2 gene-transduced tumor-infiltrating lymphocytes